凯发一触即发

目录产品 » Trastuzumab Immunogenicity Kit (Bridging ELISA)
Trastuzumab Immunogenicity Kit (Bridging ELISA)

Trastuzumab Immunogenicity Kit (Bridging ELISA)

Figure 1: Trastuzumab Immunogenicity Kit (Bridging ELISA) standard curve.

Trastuzumab Immunogenicity Kit (Bridging ELISA)

Figure 2. MRD analysis of the Kit

Trastuzumab Immunogenicity Kit (Bridging ELISA)

GenScript Trastuzumab Immunogenicity Kit (Bridging ELISA) is designed for detection of anti-Trastuzumab antibody in serum and plasma samples. This kit utilizes a validated bridgingimmunoassay method based on the FDA, EMA and NMPA Immunogenicity Guidelines. Through rigorous validation studies, the kit has been demonstrated high sensitivity, specificity, and is free from matrix effects. It is an ideal tool for the analysis of ADA against Trastuzumab.
L01007
¥4980

联系凯发一触即发
Product Description Trastuzumab, also known as Herceptin, is a human epidermal growth factor receptor 2 (HER2) inhibitor for the treatment of breast cancer. Trastuzumab is a recombinant humanized IgG1 kappa monoclonal antibody. It binds to the extracellular domain of the HER2 protein on the on the surface of HER2-positive tumor cells with high affinity. Trastuzumab can suppress the cells growth and proliferation by blocking the ability of the cancer cells to receive chemical signals.
Antibody drugs have the possibility to generate anti-drug antibodies (ADAs), which may alter drug clearance and neutralize target binding, causing reduction of drug efficacy. The immunogenicity of antibody drugs may cause anaphylaxis, infusion reactions, and immune complex disorders. Therefore, it is important to assess the presence and impact of Trastuzumab ADAs on exposure, safety, and efficacy.
GenScript Trastuzumab Immunogenicity Kit (Bridging ELISA) is designed for detection of anti-Trastuzumab antibody in serum and plasma samples. This kit utilizes a validated bridging immunoassay method based on the FDA, EMA and NMPA Immunogenicity Guidelines. Through rigorous validation studies, the kit has been demonstrated high sensitivity, specificity, and is free from matrix effects. It is an ideal tool for the analysis of ADA against Trastuzumab.

Sensitivity 0.78 ng/mL
Detection Range 0.78-50 ng/mL
Precision Intra-Assay: CV≤10%
Inter-Assay: CV≤15%
Minimum required dilution (MRD) 1:5, validated non-human primate plasma
Hook Effect Not observed at 3,200 ng/mL of anti-Trastuzumab antibodies
Conveniency All reagents and buffers for the test are provided and the test can be completed within 2 hours
Kit Contents
Component Quantity/Size Part No.
Capture Plate 1 plate R1-80
Standard Stock 1 vial (50 μL) R1-10
Biotin Trastuzumab 1 bottle (12 mL) R1-20
Streptavidin-HRP 1 bottle (12 mL) R1-30
Sample Dilution Buffer 1 bottle (60 mL) R1-60
20× Wash Solution 1 bottle (60 mL) R1-70
Stop Solution 1 bottle (6 mL) A1-50
TMB Solution 1 bottle (12 mL) A1-40
Plate Sealer 2 pieces N/A
Storage The unopened kit is stable for at least 12 months from the date of manufacture at 2°C to 8°C, and the opened kit is stable for up to 1 month from the date of opening at 2°C to 8°C.

Assay Principle The GenScript Trastuzumab Immunogenicity ELISA Kit is a bridging immunoassay that utilizes a microplate coated with the Trastuzumab. When standards or samples are added to the capture plate, anti-Trastuzumab antibodies can be captured on the plate. The biotin-conjugated Trastuzumab is then added to interact with the anti-Trastuzumab antibodies bound on the plate. After a washing step, horseradish peroxidase conjugated streptavidin (Streptavidin-HRP) is added and to react with the 3,3',5,5'-Tetramethylbenzidine solution (TMB Solution) to develop a blue product in the solution. The reaction is stopped by adding stop solution, which turns the color yellow and the absorbance can be read at 450 nm by a microplate reader. The intensity of the reaction color is directly proportional to the concentration of antibodies to Trastuzumab in samples.
Reference 1.      Immunogenicity Testing of Therapeutic Protein Products — Developing and Validating Assays for Anti-Drug Antibody Detection.
2.      Immunogenicity of Trastuzumab in patients with advanced tumors.
3.      Technical Guideline on Immunogenicity of Therapeutic Agents, NMPA, 2021.03.
4.      Immunogenicity Testing of Therapeutic Protein Products- Developing and Validating Assays for Anti-Drug Antibody Detection Guidance for Industry, January 2019.
5.      Guideline on Immunogenicity assessment of biotechnology-derived therapeutic proteins (EMEA/CHMP/BMWP/14327/2006 Rev 1), 1st Dec 2017.

  • Trastuzumab Immunogenicity Kit (Bridging ELISA)
  • Trastuzumab Immunogenicity Kit (Bridging ELISA)

  • Trastuzumab Immunogenicity Kit (Bridging ELISA)
  • Trastuzumab Immunogenicity Kit (Bridging ELISA)

    Figure 1: Trastuzumab Immunogenicity Kit (Bridging ELISA) standard curve.

  • Trastuzumab Immunogenicity Kit (Bridging ELISA)
  • Trastuzumab Immunogenicity Kit (Bridging ELISA)

    Figure 2. MRD analysis of the Kit


For research use only. Not intended for human and animal therapeutic or diagnostic use.


喜欢新升级的网站吗?

讨厌

不喜欢

一般

喜欢

非常喜欢

*